Prot #849-002: A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date9/10/209/10/23

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #849-002)
  • Mirati Therapeutics Inc. (Prot #849-002)